AZ-23

AZ-23 is an ATP-competitive and orally bioavailable Trk kinase A/B/C inhibitor with IC50s of 2 nM (TrkA), 8 nM (TrkB), 24 nM (FGFR1), 52 nM (Flt3), 55 nM (Ret), 84 nM (MuSk), 99 nM (Lck), respectively.

Product Specifications

CAS Number

[915720-21-7]

Product Name Alternative

AZD1332

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Trk Receptor

Type

Reference compound

Related Pathways

Neuronal Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/AZ-23.html

Purity

98.92

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

CC(OC1=CC(NC2=NC(N[C@H](C3=NC=C(F)C=C3)C)=NC=C2Cl)=NN1)C

Molecular Formula

C17H19ClFN7O

Molecular Weight

391.83

Precautions

H302, H315, H319, H335

References & Citations

[1]Thress K, et al. Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway. Mol Cancer Ther. 2009 Jul; 8 (7) :1818-27.